Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors

被引：0
|
作者：
Keystone, E.
Pope, J. E.
Fleischmann, R.
Emery, P.
Chubick, A.
Dougados, M.
Baldassare, A. R.
Bathon, J. M.
Hessey, E.
Totoritis, M.
Cooper, S.
机构：
[1] Univ Toronto, Dept Rheumatol, Toronto, ON, Canada
[2] Univ Western Ontario, St Josephs Hlth Ctr, London, ON N6A 4V2, Canada
[3] Univ Texas, SW Med Ctr, Dallas, TX USA
[4] Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England
[5] Baylor Univ, Med Ctr, Ctr Arthritis, Dallas, TX USA
[6] Hop Cochin, Dept Rheumatol, F-75674 Paris, France
[7] St Louis Univ, Dept Internal Med, St Louis, MO 63103 USA
[8] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA
[9] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[10] Biogen Idec, San Diego, CA USA
来源：
JOURNAL OF RHEUMATOLOGY | 2007年 / 34卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1617 / 1618
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of rituximab in active RA patients who experienced inadequate responses to one or more TNF inhibitors
    Cohen, S. B.
    Greenwald, M.
    Dougados, M.
    Emery, P.
    Furie, R.
    Shaw, T.
    Totoritis, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 108 - 109
  • [32] Efficacy of rituximab in active RA patients with an inadequate response toone or more TNF inhibitors
    Kremer, J. M.
    Maksymowych, W. P.
    Tony, H.
    Tak, P. P.
    Luggen, M.
    Mariette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1611 - 1611
  • [33] Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study).
    Keystone, Edward
    Emery, Paul
    Peterfy, Charles G.
    Tak, Paul P.
    Cohen, Stanley B.
    Genovese, Mark C.
    Williams, Sarah
    Totoritis, Mark C.
    Cravets, Matt W.
    Shaw, Tim
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S542 - S543
  • [34] Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (Reflex study)
    Keystone, E.
    Pope, J. E.
    Emery, P.
    Peterfy, C. G.
    Tak, P. P.
    Cohen, S.
    Genovese, M.
    Williams, S.
    Totoritis, M.
    Cravets, M.
    Shaw, T.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1619 - 1619
  • [35] Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex study)
    Keystone, E.
    Emery, P.
    Peterfy, C. G.
    Tak, P. P.
    Cohen, S.
    Genovese, M.
    Williams, S.
    Totoritis, M.
    Cravets, M.
    Shaw, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 58 - 58
  • [36] Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
    Burmester, Gerd
    Van den Bosch, Filip
    Bessette, Louis
    Kivitz, Alan
    Li, Yihan
    Friedman, Alan
    Pangan, Aileen
    Camp, Heidi
    Kremer, Joel
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [37] Efficacy and safety of repeat treatment courses of rituximab (RTX) in RA patients (pts) with inadequate response (IR) to tumor necrosis factor (TNF) inhibitors: Long-term experience from the REFLEX 2 study
    Keystone, Edward C.
    Fleischmarm, Roy M.
    Emery, Paul
    Chubick, Andrew
    Dougados, Maxime R.
    Baldassare, Andrew R.
    Bathon, Joan M.
    Hessey, Eva
    Hagerty, David
    Safa-Leathers, Simon
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S303 - S303
  • [38] Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors
    Fleischmann, Roy
    Genovese, Mark C.
    Maslova, Karina
    Leher, Henry
    Praestgaard, Amy
    Burmester, Gerd R.
    RHEUMATOLOGY, 2021, 60 (11) : 4991 - 5001
  • [39] Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors
    Keystone, Edward
    Cohen, Stanley B.
    Emery, Paul
    Kremer, Joel M.
    Dougados, Maxime R.
    Loveless, James E.
    Chung, Carol
    Wong, Pamela
    Lehane, Patrica B.
    Tyrrell, Helen
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S548
  • [40] Prolonged efficacy of rituximab in rheumatoid arthritis patients and inadequate response to one or more TNF inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (reflex study)
    Cohen, Stanley
    Cividino, Alfred
    Emery, Paul
    Greenwald, Maria
    Dougados, Maxime
    Furie, Richard
    Burmester, Gerd-Rudiger
    Williams, S.
    Cravets, Matthew
    Magrini, F.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1604 - 1605
12345